Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


  1. 2023
  2. Published

    Characteristics of de novo cancer in liver transplant recipients

    Riis, T. H., Møller, D. L., Høgh, J., Knudsen, A. D., Rostved, A. A., Akdag, D., Kirkby, N., Lassen, Ulrik Niels, Rasmussen, A., Hillingsø, Jens Georg & Pommergaard, Hans-Christian L, 2023, In: APMIS. 131, 4, p. 135-141 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

    Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J-Y., Italiano, A., Yonemori, K., Cho, D. C., de Vos, F. Y. F. L., Moreau, P., Fernandez, E. E., Schellens, J. H. M., Zielinski, C. C., Redhu, S., Boran, A. & 3 others, Passos, V. Q., Ilankumaran, P. & Bang, Y., 2023, In: Nature Medicine. 29, 5, p. 1103-1112 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Impact of multimorbidity and polypharmacy on mortality after cancer: a nationwide registry-based cohort study in Denmark 2005–2017

    Thomsen, M. K., Løppenthin, K. B., Bidstrup, P. E., Andersen, E. W., Dalton, Susanne Oksbjerg, Petersen, L. N., Pappot, Helle, Mortensen, C. E., Christensen, Mikkel Bring, Frølich, Anne, Lassen, Ulrik Niels & Johansen, Christoffer, 2023, In: Acta Oncologica. 62, 12, p. 1653-1660 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy

    Borch, A., Bjerregaard, A. M., Araujo Barbosa de Lima, V., Østrup, O., Yde, C. W., Eklund, A. C., Mau-Sørensen, M., Barra, C., Svane, Inge Marie, Nielsen, Finn Cilius, Funt, S. A., Lassen, Ulrik Niels & Hadrup, S. R., 2023, In: Frontiers in Genetics. 14, 13 p., 1058605.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    New pathogenic germline variants identified in mesothelioma

    Belcaid, L., Bertelsen, B., Wadt, Karin Anna Wallentin, Tuxen, I., Spanggaard, I., Højgaard, M., Sørensen, Jens Benn, Ravn, J., Lassen, Ulrik Niels, Nielsen, Finn Cilius, Rohrberg, K. & Westmose Yde, C., 2023, In: Lung Cancer. 179, 8 p., 107172.

    Research output: Contribution to journalReviewResearchpeer-review

  7. Published

    Precision cancer medicine: Concepts, current practice, and future developments

    Edsjö, A., Holmquist, L., Geoerger, B., Nowak, F., Gomon, G., Alix-Panabières, C., Ploeger, C., Lassen, Ulrik Niels, Le Tourneau, C., Lehtiö, J., Ott, P. A., von Deimling, A., Fröhling, S., Voest, E., Klauschen, F., Dienstmann, R., Alshibany, A., Siu, L. L. & Stenzinger, A., 2023, In: Journal of Internal Medicine. 294, 4, p. 455-481 27 p.

    Research output: Contribution to journalReviewResearchpeer-review

  8. Published

    ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial

    Kringelbach, T., Højgaard, M., Rohrberg, K., Spanggaard, I., Laursen, Britt Elmedal, Ladekarl, M., Haslund, C. A., Harsløf, L., Belcaid, L., Gehl, Julie, Søndergaard, L., Eefsen, R. L., Hansen, K. H., Kodahl, A. R., Jensen, L. H., Holt, M. I., Oellegaard, T. H., Yde, C. W., Ahlborn, L. B. & Lassen, Ulrik Niels, 2023, In: BMC Cancer. 23, 1, 12 p., 182.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Putting data to work for precision medicine

    Bjerrum, A. & Lassen, Ulrik Niels, 2023, In: Cell Reports Medicine. 4, 7, 3 p., 101090.

    Research output: Contribution to journalComment/debateResearchpeer-review

  10. Published

    Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

    Omuro, A., Brandes, A. A., Carpentier, A. F., Idbaih, A., Reardon, D. A., Cloughesy, T., Sumrall, A., Baehring, J., van den Bent, M., Bähr, O., Lombardi, G., Mulholland, P., Tabatabai, G., Lassen, U., Sepulveda, J. M., Khasraw, M., Vauleon, E., Muragaki, Y., Di Giacomo, A. M., Butowski, N. & 9 others, Roth, P., Qian, X., Fu, A. Z., Liu, Y., Potter, V., Chalamandaris, A. G., Tatsuoka, K., Lim, M. & Weller, M., 2023, In: Neuro-Oncology. 25, 1, p. 123-134 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. Published

    Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator

    Stenzinger, A., Cuffel, B., Paracha, N., Vail, E., Garcia-Foncillas, J., Goodman, C., Lassen, Ulrik Niels, Vassal, G. & Sullivan, S. D., 2023, In: Oncologist. 28, 5, p. e242-e253

    Research output: Contribution to journalJournal articleResearchpeer-review

  12. Published

    The Neurogenome study: Comprehensive molecular profiling to optimize treatment for Danish glioblastoma patients

    Nørøxe, D. S., Maarup, S., Fougner, Vincent Nicolay, Muhic, A., Møller, Søren, Urup, T., Lü, Maya Jeje Schuang, Weischenfeldt, Joachim Lütken, Hansen, Adam Espe, Skovgaard Poulsen, H., Lassen, Ulrik Niels & Hasselbalch, B., 2023, In: Neuro-Oncology Advances. 5, 1, 8 p., vdad137.

    Research output: Contribution to journalJournal articleResearchpeer-review

  13. 2022
  14. Published

    Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study

    Briggs, A., Paracha, N., Rosettie, K., Upton, A., Bokemeyer, C., Lassen, Ulrik Niels & Sullivan, S. D., Jan 2022, In: Oncology. 100, 2, p. 124–129 6 p.

    Research output: Contribution to journalLetterResearchpeer-review

  15. Published

    Changes in key recruitment performance metrics from 2008-2019 in industrysponsored phase III clinical trials registered at ClinicalTrials.gov

    Brøgger-Mikkelsen, Mette, Zibert, J. R., Andersen, A. D., Lassen, Ulrik Niels, Hædersdal, Merete, Ali, Z. & Thomsen, Simon Francis, 2022, In: PLoS ONE. 17, 7 July, p. 1-15 e0271819.

    Research output: Contribution to journalJournal articleResearchpeer-review

  16. Published

    Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung

    Lazar, V., Raynaud, J., Magidi, S., Bresson, C., Martini, J. F., Galbraith, S., Wunder, F., Onn, A., Batist, G., Girard, N., Lassen, U., Pramesh, C. S., Al-Omari, A., Ikeda, S., Berchem, G., Blay, J. Y., Solomon, B., Felip, E., Tabernero, J., Rubin, E. & 5 others, Philip, T., Porgador, A., Berindan-Neagoe, I., Schilsky, R. L. & Kurzrock, R., 2022, In: Therapeutic Advances in Medical Oncology. 14, p. 1-15 15 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  17. Published

    Comparative Effectiveness of Larotrectinib and Entrectinib for TRK Fusion Cancer

    Carlson, J. J., Italiano, A., Brose, M. S., Federman, N., Lassen, Ulrik Niels, Kummar, S. & Sullivan, S. D., 2022, In: American Journal of Managed Care. 28, p. S26-S32

    Research output: Contribution to journalJournal articleResearchpeer-review

  18. Published

    Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers

    Drilon, A., Tan, D. S. W., Lassen, Ulrik Niels, Leyvraz, S., Liu, Y., Patel, J. D., Rosen, L., Solomon, B., Norenberg, R., Dima, L., Brega, N., Shen, L., Moreno, V., Kummar, S. & Lin, J. J., 2022, In: JCO Precision Oncology. 6, 10 p., e2100418.

    Research output: Contribution to journalJournal articleResearchpeer-review

  19. Published

    Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact

    Jacobsen, I. C., Spanggaard, I., Højgaard, M., Belcaid, L., Qvortrup, Camilla, Yde, C. W., Schmidt, A. Y., Nielsen, Finn Cilius, Willemoe, G. L., Dam, M. S., Lassen, Ulrik Niels & Staal Rohrberg, K., 2022, In: Acta Oncologica. 61, 12, p. 1499-1506 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  20. Published

    Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation

    Fougner, V., Hasselbalch, B., Lassen, Ulrik Niels, Weischenfeldt, Joachim Lütken, Poulsen, H. S. & Urup, T., 2022, In: Neuro-Oncology Advances. 4, 1, vdac157.

    Research output: Contribution to journalReviewResearchpeer-review

  21. Published

    Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers

    Garcia‐foncillas, J., Bokemeyer, C., Italiano, A., Keating, K., Paracha, N., Fellous, M., Marian, M., Fillbrunn, M., Gao, W., Ayyagari, R. & Lassen, Ulrik Niels, 2022, In: Cancers. 14, 7, 15 p., 1793.

    Research output: Contribution to journalJournal articleResearchpeer-review

  22. Published

    Late effects–the new focus of follow-up

    Johansen, Christoffer, von Heymann, A., Rafn, B. S., Borgquist, S., Christiansen, P., Christensen, P., Zachariae, R., Pappot, Helle & Lassen, Ulrik Niels, 2022, In: Acta Oncologica. 61, 10, p. 1163-1164

    Research output: Contribution to journalEditorialResearch

  23. Published

    Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor

    Rafaeva, Maria, Horton, E. R., Jensen, A. R. D., Madsen, C. D., Reuten, R., Willacy, O., Brøchner, Christian Beltoft, Jensen, Thomas Hartvig Lindkær, Zornhagen, Kamilla Westarp, Crespo Bravo, Marina, Grønseth, D. S., Nielsen, S. R., Idorn, M., Straten, P. T., Rohrberg, K., Spanggaard, I., Højgaard, M., Lassen, Ulrik Niels, Erler, Janine & Mayorca Guiliani, Alejandro Enrique, 2022, In: Advanced Healthcare Materials. 11, 1, 2100684.

    Research output: Contribution to journalJournal articleResearchpeer-review

  24. Published

    Patients in phase 1 cancer trials: psychological distress and understanding of trial information

    Gad, K. T., Lassen, Ulrik Niels, Duun-Henriksen, A. K., Dalton, Susanne Oksbjerg, Mau-Sørensen, M., Bidstrup, P. E., Høeg, B. L., Rohrberg, K. S., Spanggard, I., von Heymann, A. & Johansen, Christoffer, 2022, In: Acta Oncologica. 61, 3, p. 341-348 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  25. Published

    Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

    Yang, J. C. H., Brose, M. S., Castro, G., Kim, E. S., Lassen, Ulrik Niels, Leyvraz, S., Pappo, A., López-Ríos, F., Reeves, J. A., Fellous, M., Penault-Llorca, F., Rudzinski, E. R., Tabatabai, G., Vassal, G., Drilon, A. & Trent, J., 2022, In: BMC Cancer. 22, 1, 625.

    Research output: Contribution to journalJournal articleResearchpeer-review

  26. Published

    TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy

    Eriksen, M., Yde, C. W., Ahlborn, L. B., Qvortrup, Camilla, Lassen, Ulrik Niels, Højgaard, M., Spanggaard, I. & Rohrberg, K. S., 2022, In: European Journal of Cancer. 174, S1, p. S118

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  27. Published

    Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

    Lazar, V., Girard, N., Raymond, E., Martini, J., Galbraith, S., Raynaud, J., Bresson, C., Solomon, B., Magidi, S., Nechushtan, H., Onn, A., Berger, R., Chen, H., Al-omari, A., Ikeda, S., Lassen, U., Sekacheva, M., Felip, E., Tabernero, J., Batist, G. & 10 others, Spatz, A., Pramesh, C. S., Girard, P., Blay, J., Philip, T., Berindan-neagoe, I., Porgador, A., Rubin, E., Kurzrock, R. & Schilsky, R. L., 2022, In: JCO Precision Oncology. 6, 12 p., e2200072.

    Research output: Contribution to journalJournal articleResearchpeer-review

  28. Published

    Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study

    Nørøxe, D. S., Flynn, A., Yde, C. W., Østrup, O., Nielsen, Finn Cilius, Skjøth, Jane, Brennum, J., Hamerlik, P., Weischenfeldt, Joachim Lütken, Skovgaard Poulsen, H. & Lassen, Ulrik Niels, 2022, In: Molecular Oncology. 16, 1, p. 206-218

    Research output: Contribution to journalJournal articleResearchpeer-review

  29. 2021
  30. Published

    Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types

    Araujo B. de Lima, V., Hansen, M., Spanggaard, I., Rohrberg, K., Reker Hadrup, S., Lassen, Ulrik Niels & Svane, Inge Marie, 25 Mar 2021, In: Frontiers in Oncology. 11, 11 p., 558248.

    Research output: Contribution to journalJournal articleResearchpeer-review

  31. Published

    Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology

    Rohrberg, K. S. & Lassen, Ulrik Niels, 2021, In: Drugs. 81, 4, p. 445-452 8 p.

    Research output: Contribution to journalReviewResearchpeer-review

  32. Published

    Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors

    Wick, A., Bahr, O., Schuler, M., Rohrberg, K., Chawla, S. P., Janku, F., Schiff, D., Heinemann, V., Narita, Y., Lenz, H. J., Ikeda, M., Ando, Y., Wick, W., Steinbach, J. P., Burger, M. C., Wenger, K., Lassen, U., Sankhala, K. K., Roggia, C., Genvresse, I. & 11 others, Munhoz, C., Rentzsch, C., Reschke, S., Langer, S., Wagner, M., Kaulfuss, S., Cai, C., Lagkadinou, E., Jeffers, M., Peña, C. & Tabatabai, G., 2021, In: Clinical Cancer Research. 27, 10, p. 2723-2733 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  33. 2020
  34. Published

    Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer – Authors' reply

    Subbiah, V., Lassen, Ulrik Niels, Gasal, E., Burgess, P. & Wainberg, Z. A., 1 Nov 2020, In: The Lancet Oncology. 21, 11, p. e516 1 p.

    Research output: Contribution to journalComment/debateResearch

  35. Published

    Total burden of disease in cancer patients at diagnosis—a Danish nationwide study of multimorbidity and redeemed medication

    Loeppenthin, K., Dalton, Susanne Oksbjerg, Johansen, Christoffer, Andersen, E., Christensen, Mikkel Bring, Pappot, Helle, Petersen, L. N., Thisted, L. B., Frølich, A., Mortensen, C. E., Lassen, Ulrik Niels, Ørsted, J. & Bidstrup, P. E., 15 Sep 2020, In: British Journal of Cancer. 123, 6, p. 1033-1040 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  36. Published

    Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

    Subbiah, V., Lassen, Ulrik Niels, Élez, E., Italiano, A., Curigliano, G., Javle, M., De Braud, F., Prager, G. W., Greil, R., Stein, A., Fasolo, A., Schellens, J. H. M., Wen, P. Y., Viele, K., Boran, A. D., Gasal, E., Burgess, P., Ilankumaran, P. & Wainberg, Z. A., 1 Sep 2020, In: The Lancet Oncology. 21, 9, p. 1234-1243 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  37. Published

    Distress and perceived information among patients in phase I trials and their relatives: A prospective study

    Gad, K. T., Dalton, Susanne Oksbjerg, Envold, P. B., Duun-henriksen, A. K., Lassen, Ulrik Niels, Mau-sørensen, M., Rohrberg, K. S., Spanggaard, I., Von Heymann, A., Høeg, B. L. & Johansen, Christoffer, 1 Sep 2020, In: Annals of Oncology. 31, p. S497 1 p., 591P .

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  38. Published

    Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome

    Araujo B de Lima, V., Borch, A., Hansen, M., Draghi, A., Spanggaard, I., Rohrberg, K., Reker Hadrup, S., Lassen, Ulrik Niels & Svane, Inge Marie, Apr 2020, In: Cytotherapy. 22, 4, p. 204-213 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  39. Published

    Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma

    Even, C., Lassen, Ulrik Niels, Merchan, J., Le Tourneau, C., Soria, J. C., Ferte, C., Ricci, F., Diener, J. T., Yuen, E., Smith, C., Oakley, G. J., Benhadji, K. A. & Massard, C., Apr 2020, In: Investigational New Drugs. 38, 2, p. 402-409

    Research output: Contribution to journalJournal articleResearchpeer-review

  40. Published

    Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

    Hong, D. S., Concin, N., Vergote, I., de Bono, J. S., Slomovitz, B. M., Drew, Y., Arkenau, H-T., Machiels, J-P., Spicer, J. F., Jones, R., Forster, M. D., Cornez, N., Gennigens, C., Johnson, M. L., Thistlethwaite, F. C., Rangwala, R. A., Ghatta, S., Windfeld, K., Harris, J. R., Lassen, U. N. & 1 others, Coleman, R. L., 15 Mar 2020, In: Clinical Cancer Research. 26, 6, p. 1220-1228 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  41. Published

    Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Urup, T., Gillberg, Linn, Kaastrup, K., Lü, M. J. S., Michaelsen, Signe Regner, Andrée Larsen, V., Christensen, I. J., Broholm, H., Lassen, Ulrik Niels, Grønbæk, Kirsten & Poulsen, H. S., 2020, In: Molecular Oncology. 14, 5, p. 964-973

    Research output: Contribution to journalJournal articleResearchpeer-review

  42. Published

    Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours

    Lassen, Ulrik Niels, 2020, In: Lancet Oncology. 21, 2, p. 193-194

    Research output: Contribution to journalComment/debateResearch

  43. Published

    Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study

    Nørøxe, D. S., Yde, C. W., Østrup, O., Michaelsen, Signe Regner, Schmidt, A. Y., Kinalis, S., Torp, M. H., Skjøth‐Rasmussen, J., Brennum, J., Hamerlik, P., Poulsen, H. S., Nielsen, Finn Cilius & Lassen, Ulrik Niels, 2020, In: Molecular Oncology.

    Research output: Contribution to journalJournal articleResearchpeer-review

  44. Published

    Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer: An intra-patient comparative analysis

    Italiano, A., Nanda, S., Briggs, A., Garcia-Foncillas, J., Lassen, Ulrik Niels, Vassal, G., Kummar, S., van Tilburg, C. M., Hong, D. S., Laetsch, T. W., Keating, K., Reeves, J. A., Fellous, M., Childs, B. H., Drilon, A. & Hyman, D. M., 2020, In: Cancers. 12, 11, p. 1-10 10 p., 3246.

    Research output: Contribution to journalJournal articleResearchpeer-review

  45. Published

    Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin

    Hassan, R., Alewine, C., Mian, I., Spreafico, A., Siu, L. L., Gomez-Roca, C., Delord, J. P., Italiano, A., Lassen, Ulrik Niels, Soria, J. C., Bahleda, R., Thomas, A., Steinberg, S. M., Peer, C. J., Figg, W. D., Niederfellner, G., Méresse Naegelen, V. & Pastan, I., 2020, In: Cancer. 126, 22, p. 4936-4947 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  46. Published

    Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

    Bono, P., Massard, C., Peltola, K. J., Azaro, A., Italiano, A., Kristeleit, R. S., Curigliano, G., Lassen, Ulrik Niels, Arkenau, H. T., Hakulinen, P., Garratt, C., Ikonen, T., Mustonen, M. V. J. & Rodon, J. A., 2020, In: ESMO Open. 5, 6, 11 p., e001081.

    Research output: Contribution to journalJournal articleResearchpeer-review

  47. Published

    Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays

    Pfarr, N., Kirchner, M., Lehmann, U., Leichsenring, J., Merkelbach-Bruse, S., Glade, J., Hummel, M., Stögbauer, F., Lehmann, A., Trautmann, M., Kumbrink, J., Jung, A., Dietmaier, W., Endris, V., Kazdal, D., Evert, M., Horst, D., Kreipe, H., Kirchner, T., Wardelmann, E. & 6 others, Lassen, Ulrik Niels, Büttner, R., Weichert, W., Dietel, M., Schirmacher, P. & Stenzinger, A., 2020, In: Genes Chromosomes and Cancer. 59, 3, p. 178-188 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  48. 2019
  49. Published

    An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer

    Morgensztern, D., Karaseva, N., Felip, E., Delgado, I., Burdaeva, O., Dómine, M., Lara, P., Paik, P. K., Lassen, Ulrik Niels, Orlov, S., Trigo, J., Shomova, M., Baker-Neblett, K., Vasquez, J., Wang, X., Yan, L., Mitrica, I., DeYoung, M. P. & Garrido, P., Oct 2019, In: Lung Cancer. 136, p. 74-79

    Research output: Contribution to journalJournal articleResearchpeer-review

  50. Published

    Socioeconomic Differences in Referral to Phase I Cancer Clinical Trials: A Danish Matched Cancer Case-Control Study

    Gad, K. T., Johansen, Christoffer, Duun-Henriksen, A. K., Krøyer, A., Olsen, M. H., Lassen, Ulrik Niels, Mau-Sørensen, M. & Dalton, Susanne Oksbjerg, 1 May 2019, In: Journal of Clinical Oncology. 37, 13, p. 1111-1119

    Research output: Contribution to journalJournal articleResearchpeer-review

  51. Published

    Application of cell-free DNA for genomic tumor profiling: a feasibility study

    Ahlborn, L. B., Rohrberg, K. S., Gabrielaite, M., Tuxen, I. V., Yde, C. W., Spanggaard, I., Santoni Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik Niels, Mau-Sorensen, M. & Østrup, O., Feb 2019, In: OncoTarget. 10, 14, p. 1388-1398

    Research output: Contribution to journalJournal articleResearchpeer-review

  52. Published

    A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24

    Mirza, M. R., Bergmann, T. K., Mau-Sørensen, M., Christensen, R. D., Åvall-Lundqvist, E., Birrer, M. J., Jørgensen, M., Roed, H., Malander, S., Nielsen, F., Lassen, Ulrik Niels, Brøsen, K., Bjørge, L. & Mäenpää, J., 2019, In: Cancer Chemotherapy and Pharmacology. 84, 4, p. 791-798 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  53. Published

    A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

    Cejalvo, J. M., Jacob, W., Fleitas Kanonnikoff, T., Felip, E., Navarro Mendivil, A., Martinez Garcia, M., Taus Garcia, A., Leighl, N., Lassen, Ulrik Niels, Mau-Soerensen, M., Adessi, C., Michielin, F., James, I., Ceppi, M., Hasmann, M., Weisser, M. & Cervantes, A., 2019, In: ESMO Open. 4, 4, 7 p., e000532.

    Research output: Contribution to journalJournal articleResearchpeer-review

  54. Published

    Actively personalized vaccination trial for newly diagnosed glioblastoma

    Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., thor Straten, P., Martínez-Ricarte, F., Ponsati, B., Okada, H., Lassen, U., Admon, A., Ottensmeier, C. H., Ulges, A., Kreiter, S., von Deimling, A. & 44 others, Skardelly, M., Migliorini, D., Kroep, J. R., Idorn, M., Rodon, J., Piró, J., Poulsen, H. S., Shraibman, B., McCann, K., Mendrzyk, R., Löwer, M., Stieglbauer, M., Britten, C. M., Capper, D., Welters, M. J. P., Sahuquillo, J., Kiesel, K., Derhovanessian, E., Rusch, E., Bunse, L., Song, C., Heesch, S., Wagner, C., Kemmer-Brück, A., Ludwig, J., Castle, J. C., Schoor, O., Tadmor, A. D., Green, E., Fritsche, J., Meyer, M., Pawlowski, N., Dorner, S., Hoffgaard, F., Rössler, B., Maurer, D., Weinschenk, T., Reinhardt, C., Huber, C., Rammensee, H. G., Singh-Jasuja, H., Sahin, U., Dietrich, P. Y. & Wick, W., 2019, In: Nature. 565, 7738, p. 240-245 6 p.

    Research output: Contribution to journalLetterResearchpeer-review

  55. Published

    Angiotensinogen promoter methylation to predict bevacizumab response in recurrent glioblastoma patients

    Urup, T., Gillberg, Linn, Kaastrup, K., Lu, M. S., Michaelsen, Signe Regner, Larsen, V. A., Christensen, I. J., Broholm, H., Lassen, Ulrik Niels, Grønbæk, Kirsten & Poulsen, H. S., 2019, In: Neuro-Oncology. 21, Supplement 6, p. vi149

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  56. Published

    Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein

    Bang-Christensen, S. R., Pedersen, R. S., Pereira, M. A., Clausen, T. M., Løppke, C., Sand, N. T., Ahrens, T. D., Jørgensen, A. M., Lim, Y. C., Goksøyr, L., Choudhary, S., Gustavsson, T., Dagil, R., Daugaard, M., Sander, A. F., Torp, M. H., Søgaard, M., Theander, T. G., Østrup, O., Lassen, U. & 3 others, Hamerlik, P., Salanti, Ali & Agerbæk, Mette Ørskov, 2019, In: Cells. 8, 9, 21 p., 998.

    Research output: Contribution to journalJournal articleResearchpeer-review

  57. Published

    Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Nørøxe, D. S., Østrup, O., Yde, C. W., Ahlborn, L. B., Nielsen, Finn Cilius, Michaelsen, Signe Regner, Larsen, V. A., Skjøth-Rasmussen, J., Brennum, J., Hamerlik, P., Poulsen, H. S. & Lassen, Ulrik Niels, 2019, In: OncoTarget. 10, 43, p. 4397-4406 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  58. Published

    Combining PARP inhibition with PD-1 inhibitors

    Lassen, Ulrik Niels, 2019, In: The Lancet Oncology. 20, 9, p. 1196-1198 3 p.

    Research output: Contribution to journalComment/debateResearchpeer-review

  59. Published

    Copenhagen prospective personalized oncology (COPPO)—Clinical utility of using molecular profiling to select patients to phase I trials

    Tuxen, I. V., Rohrberg, K. S., Oestrup, O., Ahlborn, L. B., Schmidt, A. Y., Spanggaard, I., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Yde, C. W., Mau-Sørensen, M., Nielsen, Finn Cilius & Lassen, Ulrik Niels, 2019, In: Clinical Cancer Research. 25, 4, p. 1239-1247 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  60. Published
  61. Published

    Extracranial metastases in glioblastoma—Two case stories

    Schou Nørøxe, D., Michaelsen, Signe Regner, Broholm, H., Møller, Søren, Skovgaard Poulsen, H. & Lassen, Ulrik Niels, 2019, In: Clinical Case Reports. 7, 2, p. 289-294 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  62. Published

    High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer

    Bertelsen, B., Tuxen, I. V., Yde, C. W., Gabrielaite, M., Torp, M. H., Kinalis, S., Oestrup, O., Rohrberg, K., Spangaard, I., Santoni Rugiu, Eric, Wadt, Karin Anna Wallentin, Mau-Sorensen, M., Lassen, Ulrik Niels & Nielsen, Finn Cilius, 2019, In: npj Genomic Medicine. 4, 1, 11 p., 13.

    Research output: Contribution to journalJournal articleResearchpeer-review

  63. Published

    How I treat NTRK gene fusion-positive cancers

    Lassen, Ulrik Niels, 2019, In: ESMO Open. 4, Suppl. 2, 3 p., e000612.

    Research output: Contribution to journalReviewResearchpeer-review

  64. Published

    Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

    Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., López-Larrea, C., Hilf, N., Kuttruff, S., Song, C., Britten, C., Castle, J., Kreiter, S., Frenzel, K., Tatagiba, M., Tabatabai, G., Dietrich, P-Y., Dutoit, V., Wick, W., Platten, M. & 17 others, Winkler, F., von Deimling, A., Kroep, J., Sahuquillo, J., Martinez-Ricarte, F., Rodon, J., Lassen, Ulrik Niels, Ottensmeier, C., van der Burg, S. H., Thor Straten, P., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H., Sahin, U., Singh, H. & Admon, A., 2019, In: Molecular and Cellular Proteomics. 18, 6, p. 1255-1268 14 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  65. Published

    Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

    Viller Tuxen, I., Barlebo Ahlborn, L., Mau-Soerensen, M., Staal Rohrberg, K., Nielsen, Finn Cilius, Oestrup, O., Westmose Yde, C., Richter Vogelius, I. & Lassen, Ulrik Niels, 2019, In: British Journal of Cancer. 121, 2, p. 125-130 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  66. Published

    Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

    de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J. P., Arkenau, H. T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., Ghatta, S., Slomovitz, B. M., Spicer, J. F., Yachnin, J., Ang, J. E., Mau-Sørensen, P. M., Forster, M. D., Collins, D., Dean, E., Rangwala, R. A. & 1 others, Lassen, Ulrik Niels, 2019, In: The Lancet Oncology. 20, 3, p. 383-393 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  67. 2018
  68. Published

    Patient information in phase 1 trials: A systematic review

    Gad, K. T., Lassen, Ulrik Niels, Mau-Søerensen, M., Høybye, M. T. & Johansen, Christoffer, Mar 2018, In: Psycho-Oncology. 27, 3, p. 768-780

    Research output: Contribution to journalReviewResearchpeer-review

  69. Published

    A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors

    de Weger, V. A., Goel, S., von Moos, R., Schellens, J. H. M., Mach, N., Tan, E., Anand, S., Scott, J. W. & Lassen, Ulrik Niels, 2018, In: Cancer Chemotherapy and Pharmacology. 81, 1, p. 73-80 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  70. Published

    A systematic review of targeted agents for non-small cell lung cancer

    Vestergaard, H. H., Christensen, M. R. & Lassen, Ulrik Niels, 2018, In: Acta Oncologica. 57, 2, p. 176-186 11 p.

    Research output: Contribution to journalReviewResearchpeer-review

  71. Published

    Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

    Toft, A., Urup, T., Christensen, I. J., Michaelsen, Signe Regner, Lukram, B., Grunnet, K., Kosteljanetz, M., Larsen, V. A., Lassen, Ulrik Niels, Broholm, H. & Poulsen, H. S., 2018, In: Cancer Investigation. 36, 2, p. 165-174 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  72. Published

    Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

    Ahlborn, L. B., Tuxen, I. V., Mouliere, F., Kinalis, S., Schmidt, A. Y., Rohrberg, K. S., Santoni Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik Niels, Yde, C. W., Oestrup, O. & Mau-Sorensen, M., 2018, In: OncoTarget. 9, 66, p. 32570-32579

    Research output: Contribution to journalJournal articleResearchpeer-review

  73. Published

    Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

    Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., Turpin, B., Dowlati, A., Brose, M. S., Mascarenhas, L., Federman, N., Berlin, J., El-Deiry, W. S., Baik, C., Deeken, J., Boni, V. & 18 others, Nagasubramanian, R., Taylor, M., Rudzinski, E. R., Meric-Bernstam, F., Sohal, D. P. S., Ma, P. C., Raez, L. E., Hechtman, J. F., Benayed, R., Ladanyi, M., Tuch, B. B., Ebata, K., Cruickshank, S., Ku, N. C., Cox, M. C., Hawkins, D. S., Hong, D. S. & Hyman, D. M., 2018, In: The New England Journal of Medicine. 378, 8, p. 731-739

    Research output: Contribution to journalJournal articleResearchpeer-review

  74. Published

    First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

    Massard, C., Azaro, A., Soria, J., Lassen, Ulrik Niels, Le Tourneau, C., Sarker, D., Smith, C., Ohnmacht, U., Oakley, G., Patel, B. K. R., Yuen, E. S. M., Benhadji, K. A. & Rodon, J., 2018, In: Annals of oncology : official journal of the European Society for Medical Oncology. 29, 9, p. 1911-1917 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  75. Published

    Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival

    Michaelsen, Signe Regner, Urup, T., Olsen, L. R., Broholm, H., Lassen, Ulrik Niels & Poulsen, H. S., 2018, In: Journal of Neuro-Oncology. 137, 3, p. 533-542 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  76. Published

    Mutational landscape assessed in tumor tissue and cell-free DNA during neratinib treatment of patients with HER2 mutated solid tumors

    Spanggaard, I., Oestrup, O., Bertelsen, B., Rohrberg, K. S., de Schmidt, A. Y., Tuxen, I. V., Ahlborn, L. B., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Marvig, R. L., Lassen, Ulrik Niels, Nielsen, Finn Cilius, Yde, C. W. & Mau-Sørensen, M., 2018, In: European Journal of Cancer. 103, Suppl. 1, p. E142-E143 2 p.

    Research output: Contribution to journalConference abstract in journalResearch

  77. Published

    Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

    Johansen, M. D., Urup, T., Holst, C. B., Christensen, I. J., Grunnet, K., Lassen, Ulrik Niels, Friis, S. & Poulsen, H. S., 2018, In: Cancer Investigation. 36, 9-10, p. 512-519 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  78. Published

    Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

    Schneeweiss, A., Park-Simon, T. W., Albanell, J., Lassen, U., Cortés, J., Dieras, V., May, M., Schindler, C., Marmé, F., Cejalvo, J. M., Martinez-Garcia, M., Gonzalez, I., Lopez-Martin, J., Welt, A., Levy, C., Joly, F., Michielin, F., Jacob, W., Adessi, C., Moisan, A. & 7 others, Meneses-Lorente, G., Racek, T., James, I., Ceppi, M., Hasmann, M., Weisser, M. & Cervantes, A., 2018, In: Investigational New Drugs. 36, 5, p. 848-859 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  79. Published

    TRK Inhibition: A New Tumor-Agnostic Treatment Strategy

    Kummar, S. & Lassen, Ulrik Niels, 2018, In: Targeted Oncology. 13, 5, p. 545-556

    Research output: Contribution to journalReviewResearchpeer-review

  80. Published

    VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance

    Michaelsen, Signe Regner, Staberg, M., Pedersen, H., Jensen, K. E., Majewski, W., Broholm, H., Nedergaard, M. K., Meulengracht, C., Urup, T., Villingshøj, M., Lukacova, S., Skjøth-Rasmussen, J., Brennum, J., Kjær, Andreas, Lassen, Ulrik Niels, Stockhausen, M., Poulsen, H. S. & Hamerlik, P., 2018, In: Neuro-Oncology. 20, 11, p. 1462-1474

    Research output: Contribution to journalJournal articleResearchpeer-review

  81. 2017
  82. Published

    Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities

    Dombernowsky, T., Hædersdal, Merete, Lassen, Ulrik Niels & Thomsen, Simon Francis, Jul 2017, In: B M J Open. 7, 7, 10 p., e015579.

    Research output: Contribution to journalJournal articleResearchpeer-review

  83. Published

    Clinical trial allocation in multinational pharmaceutical companies: a qualitative study on influential factors

    Dombernowsky, T., Hædersdal, Merete, Lassen, Ulrik Niels & Thomsen, Simon Francis, Jun 2017, In: Pharmacology Research & Perspectives. 5, 3, 9 p., e00317.

    Research output: Contribution to journalJournal articleResearchpeer-review

  84. Published

    Detection of copy number alterations in cell-free tumor DNA from plasma

    Østrup, O., Ahlborn, L. B., Lassen, Ulrik Niels, Mau-Sørensen, M. & Nielsen, Finn Cilius, Jun 2017, In: BBA Clinical. 7, p. 120-126 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  85. Published

    Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

    Urup, T., Staunstrup, L. M., Michaelsen, Signe Regner, Vitting-Seerup, K., Bennedbæk, M., Toft, A., Olsen, L. R., Jønson, L., Issazadeh-Navikas, Shohreh, Broholm, H., Hamerlik, P., Poulsen, H. S. & Lassen, Ulrik Niels, 18 Apr 2017, In: BMC Cancer. 17, 10 p., 278.

    Research output: Contribution to journalJournal articleResearchpeer-review

  86. Published

    Concordance of mutation detection in circulating tumor DNA in early clinical trials using different blood collection protocols

    Ahlborn, L. B., Madsen, M., Jonson, L., Nielsen, Finn Cilius, Lassen, Ulrik Niels, Yde, C. W. & Mau-Sorensen, M., 2017, In: Clinical Laboratory. 63, 10, p. 1755-1759

    Research output: Contribution to journalJournal articleResearchpeer-review

  87. Published

    Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

    Jacobsen, K., Bertran-Alamillo, J., Molina, M. A., Teixidó, C., Karachaliou, N., Pedersen, M. H., Castellví, J., Garzón, M., Codony-Servat, C., Codony-Servat, J., Giménez-Capitán, A., Drozdowskyj, A., Viteri, S., Larsen, M. R., Lassen, Ulrik Niels, Felip, E., Bivona, T. G., Ditzel, H. J. & Rosell, R., 2017, In: Nature Communications. 8, 14 p., 410.

    Research output: Contribution to journalJournal articleResearchpeer-review

  88. Published

    Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

    Meulendijks, D., Jacob, W., Voest, E. E., Mau-Sorensen, M., Martinez-Garcia, M., Taus, A., Fleitas, T., Cervantes, A., Lolkema, M. P., Langenberg, M. H. G., De Jonge, M. J., Sleijfer, S., Han, J-Y., Calles, A., Felip, E., Kim, S-W., Schellens, J. H. M., Wilson, S., Thomas, M., Ceppi, M. & 11 others, Meneses-Lorente, G., James, I., Vega-Harring, S., Dua, R., Nguyen, M., Steiner, L., Adessi, C., Michielin, F., Bossenmaier, B., Weisser, M. & Lassen, Ulrik Niels, 2017, In: Clinical Cancer Research. 23, 18, p. 5406-5415

    Research output: Contribution to journalJournal articleResearchpeer-review

  89. 2016
  90. Published

    First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

    Abdul Razak, A. R., Mau-Sørensen, M., Gabrail, N. Y., Gerecitano, J. F., Shields, A. F., Unger, T. J., Saint-Martin, J. R., Carlson, R., Landesman, Y., McCauley, D., Rashal, T., Lassen, Ulrik Niels, Kim, R., Stayner, L., Mirza, M. R., Kauffman, M., Shacham, S. & Mahipal, A., Dec 2016, In: Journal of Clinical Oncology. 34, 34, p. 4142-4150 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  91. Published

    Hallmarks of glioblastoma: a systematic review

    Nørøxe, D. S., Poulsen, H. S. & Lassen, Ulrik Niels, Dec 2016, In: E S M O Open. 1, 6, 9 p., e000144.

    Research output: Contribution to journalReviewResearchpeer-review

  92. Published

    Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

    Urup, T., Michaelsen, Signe Regner, Olsen, L. R., Toft, A., Christensen, I. J., Grunnet, K., Winther, Ole, Broholm, H., Kosteljanetz, M., Issazadeh-Navikas, Shohreh, Poulsen, H. S. & Lassen, Ulrik Niels, Oct 2016, In: Molecular Oncology. 10, 8, p. 1160-1168

    Research output: Contribution to journalJournal articleResearchpeer-review

  93. Published

    Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

    Plesner, T., Arkenau, H-T., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M. C., Lassen, U. N., Laubach, J. P., Palumbo, A., Lisby, S., Basse, L., Wang, J., Sasser, A. K., Guckert, M. E., de Boer, C., Khokhar, N. Z., Yeh, H., Clemens, P. L., Ahmadi, T., Lokhorst, H. M. & 1 others, Richardson, P. G., Oct 2016, In: Blood. 128, 14, p. 1821-1828

    Research output: Contribution to journalJournal articleResearchpeer-review

  94. Published

    First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors

    Dienstmann, R., Lassen, Ulrik Niels, Cebon, J., Desai, J., Brown, M. P., Evers, S., Su, F., Zhang, W., Boisserie, F., Lestini, B., Schostack, K., Meresse, V. & Tabernero, J., Apr 2016, In: Targeted Oncology. 11, 2, p. 149-56 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  95. Published

    Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma

    Nedergaard, M. K., Michaelsen, Signe Regner, Perryman, L., Erler, Janine, Poulsen, H. S., Stockhausen, M., Lassen, Ulrik Niels & Kjær, Andreas, Mar 2016, In: Nuclear Medicine and Biology. 43, 3, p. 198-205 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  96. Published

    Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

    Meulendijks, D., Lassen, Ulrik Niels, Siu, L. L., Huitema, A. D. R., Karanikas, V., Mau-Sørensen, M., Jonker, D. J., Hansen, A. R., Simcox, M. E., Schostack, K. J., Bottino, D., Zhong, H., Roessler, M., Vega-Harring, S. M., Jarutat, T., Geho, D., Wang, K., DeMario, M., Goss, G. D. & Schellens, J. H. M., 15 Feb 2016, In: Clinical Cancer Research. 22, 4, p. 858-67 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  97. Published

    First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

    Meulendijks, D., Jacob, W., Martinez-Garcia, M., Taus, A., Lolkema, M. P., Voest, E. E., Langenberg, M. H. G., Fleitas Kanonnikoff, T., Cervantes, A., De Jonge, M. J., Sleijfer, S., Mau-Sørensen, M., Thomas, M., Ceppi, M., Meneses-Lorente, G., James, I., Adessi, C., Michielin, F., Abiraj, K., Bossenmaier, B. & 3 others, Schellens, J. H. M., Weisser, M. & Lassen, Ulrik Niels, 15 Feb 2016, In: Clinical Cancer Research. 22, 4, p. 877-85 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  98. Published

    Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma

    Persson, M., Nedergaard, M. K., Brandt-Larsen, M., Skovgaard, D., Jørgensen, Jesper Tranekjær, Michaelsen, Signe Regner, Madsen, J., Lassen, Ulrik Niels, Poulsen, H. S. & Kjær, Andreas, Feb 2016, In: Journal of Nuclear Medicine. 57, 2, p. 272-278 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  99. Published

    Actionable targets in recurrent bile duct and pancreatic cancer in a prospective cohort of patients evaluated by whole exome sequencing and SNP array analysis

    Tuxen, I. E. V., Mau-Sørensen, M., Yde, C. W., Jønson, L., Oestrup, O., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Lassen, Ulrik Niels & Nielsen, Finn Cilius, 2016, In: Journal of Clinical Oncology. 34, 15, Suppl., 1 p., e23256.

    Research output: Contribution to journalConference abstract in journalResearch

  100. Published

    Copenhagen prospective personalized oncology (CoPPO): Genomic profiling to select patients for phase 1 trials

    Tuxen, I. V., Yde, C. W., Mau-Sorensen, M., Santoni Rugiu, Eric, Lassen, Ulrik Niels & Nielsen, Finn Cilius, 2016, In: Annals of Oncology.

    Research output: Contribution to journalJournal articleResearchpeer-review

  101. Published

    Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan

    Urup, T., Dahlrot, R. H., Grunnet, K., Christensen, I. J., Michaelsen, Signe Regner, Toft, A., Larsen, V. A., Broholm, H., Kosteljanetz, M., Hansen, S., Poulsen, H. S. & Lassen, Ulrik Niels, 2016, In: Acta Oncologica. 55, 4, p. 418-22 5 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  102. Published

    Dynamics of mutant BRAF V600E in free circulating DNA (fcDNA) of non-melanoma cancer patients (pts) in response to treatment with BRAF and MEK/EGFR inhibitors

    Mau-Sørensen, M., Ahlborn, L. B., Jønson, L., Oestrup, O., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik Niels & Yde, C. W., 2016, In: Journal of Clinical Oncology. 34, 15 (Suppl. S), 11531.

    Research output: Contribution to journalConference abstract in journalResearch

  103. Published

    Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2: a retrospective case series

    Alanin, M. C., Klausen, C., Cayé-Thomasen, Per, Thomsen, C., Fugleholm, Kåre, Poulsgaard, L., Lassen, Ulrik Niels, Mau-Sørensen, M. & Hofland, K. F., 2016, In: International Journal of Neuroscience. 126, 11, p. 1002-6 5 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  104. 2015
  105. Published

    The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2

    Alanin, M. C., Klausen, C., Cayé-Thomasen, Per, Thomsen, C., Fugleholm, K., Poulsgaard, L., Lassen, Ulrik Niels, Mau-Sorensen, M. & Hofland, K. F., Dec 2015, In: European Archives of Oto-Rhino-Laryngology. 272, 12, p. 3627-3633 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  106. Published

    Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

    Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N. W. C. J., Ahmadi, T., Khan, I., Uhlar, C. M., Wang, J., Sasser, A. K., Losic, N., Lisby, S., Basse, L., Brun, N. & 1 others, Richardson, P. G., 24 Sep 2015, In: New England Journal of Medicine. 373, 13, p. 1207-19 13 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  107. Published

    Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer

    Grunnet, M., Christensen, I. J., Lassen, Ulrik Niels, Jensen, L. H., Lydolph, M., Knox, J. J., McNamara, M. G., Jitlal, M., Wasan, H., Bridgewater, J., Valle, J. W. & Mau-Sørensen, M., Jul 2015, In: European journal of cancer (Oxford, England : 1990). 51, 11, p. 1381-8 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  108. Published

    Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma

    Lassen, Ulrik Niels, Chinot, O. L., McBain, C., Mau-Sørensen, M., Larsen, V. A., Barrie, M., Roth, P., Krieter, O., Wang, K., Habben, K., Tessier, J., Lahr, A. & Weller, M., Jul 2015, In: Neuro-Oncology. 17, 7, p. 1007-15 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  109. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3

    Mau-Sørensen, M., Dittrich, C., Dienstmann, R., Lassen, Ulrik Niels, Büchler, W., Martinius, H. & Tabernero, J., May 2015, In: Cancer Chemotherapy and Pharmacology. 75, 5, p. 1065-73 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 Next

ID: 4952653